NeuroHarmonics launched its first clinical trial, evaluating its non-invasive deep-brain ultrasound platform in essential tremor. The study follows regulatory clearance from the UK's MHRA and a favorable ethics opinion, and will enroll adults whose tremor is inadequately controlled by medication. Focused ultrasound can reach deep brain structures that surface stimulation cannot. NeuroHarmonics is designing for accessibility, removing the MRI guidance and fitted mask that focused ultrasound normally requires.

NeuroHarmonics revealed the first public details of the neuromodulation platform it has been developing. The team develops a device that uses transcranial ultrasound to reach deep brain circuits without surgery. The London company, a spin-out of University College London, positions the system on accessibility, requiring no hair preparation, no mask, and no scanner, in contrast to the setup focused ultrasound normally demands. Focused ultrasound can target millimeter-scale regions in the deeper structures that surface stimulation cannot reach.